About clonoSEQ
A test that’s as mighty as today’s cancer treatments
clonoSEQ is a blood or bone marrow test that tracks the impact your treatment is having on cancer throughout your care. It is CLIA-validated in peripheral blood and bone marrow for mantle cell lymphoma (MCL).1
clonoSEQ is a blood or bone marrow test that tracks the impact your treatment is having on cancer throughout your care. It is CLIA-validated in peripheral blood and bone marrow for mantle cell lymphoma (MCL).1
clonoSEQ helps your doctor tailor treatment to your needs
clonoSEQ uses next-generation sequencing technology, an advanced testing method that decodes your cancer’s genetic information, to look for unique cancer DNA sequences
that serve as “barcodes.” After your diagnosis, clonoSEQ identifies and counts your
cancer’s unique “barcodes.” During treatment and remission, clonoSEQ can tell you and
your doctor if and how the number of “barcodes” has changed since your last MRD test.1
“clonoSEQ gives patients confidence that we are staying ahead of their disease.”
— Dr. Farhad Khimani
clonoSEQ provides the most sensitive measurement of MRD currently available1,2
When it comes to cancer, knowledge is power. By precisely tracking MRD both during and after treatment, you and your doctor can be more informed about your response to therapy—and can plan next steps accordingly.1
clonoSEQ can identify residual disease that other tests miss
While traditional tests used in MCL, such as PET/CT imaging, can help your doctor get a big-picture view of your cancer, they may miss residual disease.3 clonoSEQ is a convenient, blood-based test that provides a deeper assessment to complement imaging, which may help detect any potential relapse earlier.3-5
clonoSEQ predicted relapse in
92%
of patients a median of 34 days (range of 0-24 months) before PET/CT scans4
Measure, then treat.
Treat, then measure.
Repeat throughout your journey.
There are often several stages of treatment for MCL. By monitoring MRD at various time points, you and your doctor can track how well your treatment is working. clonoSEQ MRD testing provides additional insights into your disease to help inform what to do next.
Click through to see when your doctor may test you with clonoSEQ.
(1 of 4)
Initial diagnosis
Identify cancer cell DNA (Clonality (ID) Test)
The clonoSEQ Clonality (ID) Test provides a baseline. Because this test is done on the largest number of cancer cells, it helps clonoSEQ know which cells to look for in later tests.
(2 of 4)
Induction (or frontline) therapy
Your doctor may use clonoSEQ alongside imaging (like PET/CT scans) during and after induction treatment. This can help determine when—or if—you will receive maintenance therapy.6
(3 of 4)
Maintenance therapy and surveillance
Your doctor may continue to monitor your MRD with clonoSEQ if you move to maintenance therapy. This can help your doctor decide if or when to stop, adjust, or change your treatment. Your doctor may also want to use clonoSEQ MRD testing when you’re off therapy during surveillance. This can help them identify small amounts of returning cancer cells, which may mean it’s time to start treatment again. 4,7,8
(4 of 4)
Second-line treatment and beyond
Your doctor may want to monitor your MRD status during and after certain second-line treatments, such as BTK inhibitor or CAR-T therapy. Tracking MRD during and after treatment may help you and your doctor detect relapse sooner and provide important information to help determine next steps.5
Talk to your doctor about clonoSEQ
Here are some questions to help you start a conversation with your doctor.
- Is MRD testing with clonoSEQ right for me?
- I heard that clonoSEQ is the most sensitive MRD test available. Why does that matter for me?
- What can MRD testing with clonoSEQ tell me about my cancer?
- How will you incorporate MRD results from clonoSEQ into my treatment plan?
- At what points during the treatment process should I have a clonoSEQ MRD test?
Be sure to check in with your doctor regularly. This way, you can ensure you are on track with the MRD goals you’ve set together.
Take a look at a sample clonoSEQ report
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
References:
- clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
- Short N, et al. Am J Hematol. 2019;94(2):257-265.
- Ananth S, et al. Abstract: 1673. Poster presented at: ASH Annual Meeting; December 2023; San Diego, CA.
- Rezazadeh A, et al. Clin Lymphoma Myeloma Leuk. 2023;2152-2650.
- Shah N, et al. Abstract: 1024. Presented at: ASH Annual Meeting; December 2023; San Diego, CA.
- McQuinn D, et al. Abstract: 4407. Presented at: ASH Annual Meeting; December 2023; San Diego, CA.
- Epstein-Peterson Z, et al. Haematologica. 2023.
- Kumar A, et al. Abstract: 738. Presented at: ASH Annual Meeting; December 2023; San Diego, CA.